BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models. J Pharmacol Exp Ther 2019;371:231-41. [PMID: 31406003 DOI: 10.1124/jpet.119.261099] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Banerjee D, Patra D, Sinha A, Roy S, Pant R, Sarmah R, Dutta R, Kanta Bhagabati S, Tikoo K, Pal D, Dasgupta S. Lipid-induced monokine cyclophilin-A promotes adipose tissue dysfunction implementing insulin resistance and type 2 diabetes in zebrafish and mice models of obesity. Cell Mol Life Sci 2022;79:282. [PMID: 35511344 DOI: 10.1007/s00018-022-04306-1] [Reference Citation Analysis]
2 Mm Shehata E, A Gowayed M, El-Ganainy SO, Sheta E, Sr Elnaggar Y, Abdallah OY. Pectin coated Nanostructured Lipid Carriers for Targeted Piperine Delivery to Hepatocellular Carcinoma. Int J Pharm 2022;:121712. [PMID: 35367582 DOI: 10.1016/j.ijpharm.2022.121712] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for Chronic Hepatitis B. Virulence 2022. [PMID: 35763282 DOI: 10.1080/21505594.2022.2093444] [Reference Citation Analysis]
4 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
5 Naguib M, Abou Elfotouh M, Wifi MN. Elevated Serum Cyclophilin D Level is Associated with Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients with Diabetes Mellitus. Int J Gen Med 2021;14:4665-75. [PMID: 34434058 DOI: 10.2147/IJGM.S322986] [Reference Citation Analysis]
6 Hyun S, Park N, Nam SH, Cheon DH, Lee Y, Lim HS, Yu J. One-bead-one-compound screening approach to the identification of cyclic peptoid inhibitors of cyclophilin D as neuroprotective agents from mitochondrial dysfunction. Chem Commun (Camb) 2021;57:2388-91. [PMID: 33538721 DOI: 10.1039/d0cc08268f] [Reference Citation Analysis]
7 Li FX, Zhang QZ, Li SJ, Lin G, Huo XY, Lan Y, Yang Z. Semisynthesis of CRV431. Org Lett 2021;23:3421-5. [PMID: 33844557 DOI: 10.1021/acs.orglett.1c00881] [Reference Citation Analysis]
8 Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis. Cells 2019;8:E1409. [PMID: 31717385 DOI: 10.3390/cells8111409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sun S, Yang Q, Sheng Y, Fu Y, Sun C, Deng C. Investigational drugs with dual activity against HBV and HIV (Review). Exp Ther Med 2021;21:35. [PMID: 33262821 DOI: 10.3892/etm.2020.9467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kolic J, Beet L, Overby P, Cen HH, Panzhinskiy E, Ure DR, Cross JL, Huizinga RB, Johnson JD. Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion From Human Islets. Endocrinology 2020;161:bqaa162. [PMID: 32894758 DOI: 10.1210/endocr/bqaa162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
11 Bobardt M, Ramirez CM, Baum MM, Ure D, Foster R, Gallay PA. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLoS One 2021;16:e0251934. [PMID: 34014993 DOI: 10.1371/journal.pone.0251934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Leong KG, Ozols E, Kanellis J, Badal SS, Liles JT, Nikolic-Paterson DJ, Ma FY. Cyclophilin Inhibition Protects Against Experimental Acute Kidney Injury and Renal Interstitial Fibrosis. Int J Mol Sci 2020;22:E271. [PMID: 33383945 DOI: 10.3390/ijms22010271] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Bobardt M, Hansson MJ, Mayo P, Ure D, Foster R, Gallay P. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. PLoS One 2020;15:e0237236. [PMID: 32764799 DOI: 10.1371/journal.pone.0237236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Shojaie L, Iorga A, Dara L. Cell Death in Liver Diseases: A Review. Int J Mol Sci 2020;21:E9682. [PMID: 33353156 DOI: 10.3390/ijms21249682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
15 Ure DR, Trepanier DJ, Mayo PR, Foster RT. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs 2020;29:163-78. [DOI: 10.1080/13543784.2020.1703948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 28.0] [Reference Citation Analysis]
17 Scheuplein NJ, Bzdyl NM, Kibble EA, Lohr T, Holzgrabe U, Sarkar-Tyson M. Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria. J Med Chem 2020;63:13355-88. [PMID: 32786507 DOI: 10.1021/acs.jmedchem.0c00911] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]